Zepbound 5 mg/.5mL (Tirzepatide INJECTION, SOLUTION) 5 mg/.5mL

Tirzepatide works by activating both GIP and GLP-1 receptors, which are part of the incretin system. This increases glucose-dependent insulin secretion, lowers glucagon release, slows gastric emptying, and reduces appetite. These combined effects support weight management when the medicine is used as prescribed.

The usual dose is set by the prescriber and depends on the individual patient, treatment goals, and tolerability. A fixed regimen should not be assumed from the product name or strength alone. Follow the official label and the prescribing clinician’s instructions exactly, since dose changes are individualized.

Safety in pregnancy and breastfeeding is not established from the product description alone, so use should be discussed with a clinician before treatment. In general, pregnancy and lactation require a careful risk-benefit assessment for medicines in this class. Patients should not assume it is appropriate without medical guidance.

Submit the enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team then responds with pricing, availability, shipping details, including cold-chain handling where relevant, and the import paperwork.

Zepbound belongs to the dual GIP/GLP-1 receptor agonist class, which differs from medicines that act on a single incretin pathway. Compared with other anti-obesity treatments, it is used specifically for chronic weight management in eligible adults. Any choice between options should be made by a prescriber based on labeled use, tolerance, and clinical goals.

Because it is an injectable biologic-type product, it should be refrigerated at 2-8°C, protected from light, and not frozen or shaken. Handling should follow the package insert and local pharmacy procedures. Patients and caregivers should keep it in the original container until use and avoid exposing it to heat or freezing conditions.

Zepbound is an injection solution for subcutaneous use. That means it is given under the skin rather than by mouth or into a vein. Administration should follow the prescribing information and the instructions provided by a qualified healthcare professional or trained caregiver.

The most serious risks include pancreatitis, gallbladder disease, significant hypoglycemia when used with insulin or sulfonylureas, and dehydration-related kidney injury. Severe abdominal pain, persistent vomiting, or signs of low blood sugar should be assessed promptly. Any concerning symptoms should be reviewed by a clinician without delay.

Zepbound should not be used by patients with a personal or family history of medullary thyroid carcinoma or MEN2. It is also not appropriate for people who cannot use tirzepatide safely because of hypersensitivity or other label-based restrictions. A prescriber should screen for contraindications before treatment starts.